Gem Aromatics Ltd. (GEMAROMA) — Tipsheet

Gem Aromatics sets up Brazil subsidiary, commits up to ₹17 cr

Tipsheet Editorial — Tue, 23 Jun 2026 17:35:45 GMT

Board approves WOS in Brazil for distributing essential oils and chemicals; total commitment of ₹17 cr exceeds 1.5% of market cap. Routine auditor reappointments also cleared.

What’s new

Board approved formation of a wholly-owned subsidiary in Brazil.
Equity investment up to ₹2 cr; standby letter of credit up to ₹15 cr.
RANK & Associates reappointed internal auditor; N.L. Bhatia & Associates appointed secretarial auditor.

Why it matters

For a micro-cap with trailing revenue down 45% and PAT down 96%, a ₹17 cr overseas commitment signals strategic ambition. But the subsidiary is yet to be incorporated, and the financial impact is not immediate. The move is modest in absolute terms but material relative to the company's ₹946 cr market cap.

What we’re watching

Regulatory approvals from Brazil and RBI.
Whether the subsidiary starts contributing to revenue within FY27.
Any update on Dahej plant ramp-up from prior guidance.

The full read

Gem Aromatics' board has approved a wholly-owned subsidiary in Brazil to distribute essential oils and aromatic chemicals, the company's first overseas unit. The financial commitment is modest: ₹2 crore in equity plus a standby letter of credit of up to ₹15 crore, totalling ₹17 crore. That is over 1.5% of its ₹946 crore market cap, a material bet for a micro-cap. But the subsidiary is yet to be formed and needs approvals from Brazil and India. Meanwhile, the company faces steep headwinds with trailing revenue down 45% and PAT down 96%. The auditor reappointments are routine. The expansion signals ambition, but the proof will be in the execution.

Primary source: BSE · NSE

Gem Aromatics repeats its FY28 guidance. The transcript adds nothing.

Tipsheet Editorial — Tue, 26 May 2026 16:22:03 GMT

The full Q4 earnings call transcript reiterates the ₹1,050-1,100 cr revenue target and 16-18% EBITDA margin. No new information is disclosed.

What’s new

The transcript is a verbatim Q&A of the prior concall summary.
It repeats the Dahej facility ramp-up and phenol derivative delay discussions.
No new financial data, order wins, or strategic shifts are disclosed.

Why it matters

This is a compliance release, not a news event. The full transcript adds detail to the Q&A but no substance. The market already priced the guidance when the summary dropped.

What we’re watching

Dahej facility commissioning progress versus management's sketched timeline.
Quarterly revenue run-rate toward the ₹1,050-1,100 cr target.
Any update on phenol derivative delays impacting the 16-18% margin band.

The full read

Gem Aromatics' Q4 earnings transcript is a formality. It repeats the ₹1,050-1,100 crore FY28 revenue target and the 16-18% EBITDA margin. The Dahej facility ramp-up and phenol derivative delays were discussed again. Nothing new. The rationale confirms the transcript contains no material new information beyond the prior concall summary. This is a regulatory filing, not a catalyst. For a stock that already reacted to the initial guidance, this is a non-event. The only forward item is whether the Dahej ramp hits the timeline management has sketched.

Primary source: BSE · NSE

Gem Aromatics targets ₹1,100 cr revenue by FY28 on Dahej ramp

Tipsheet Editorial — Fri, 22 May 2026 17:11:44 GMT

Management laid out a two-year plan after a sequential Q4 recovery, but gave no guidance for the current year.

What’s new

Gem Aromatics set a FY28 revenue target of ₹1,050-1,100 cr and EBITDA margins of 16-18%.
Dahej plant, operational since February, can generate up to ₹800 cr annually at peak capacity.
Cooling agents from Dahej are being positioned as a tariff-free alternative to Chinese imports.

Why it matters

The company is staking a bold two-year target on a plant that only started production three months ago. For a micro-cap, the ₹800 cr peak potential from a single facility is material. The explicit China Plus One pitch for cooling agents is a specific, marketable claim.

What we’re watching

Actual Dahej utilization rates over the next two quarters.
Whether cooling-agent orders materialize to back up the tariff-arbitrage thesis.
Formal FY27 guidance, deferred citing geopolitical and raw-material volatility.

The full read

Gem Aromatics has a plan. Two years out, management is targeting ₹1,050-1,100 crore in revenue and 16-18% EBITDA margins. The bet is on Dahej. The greenfield plant started commercial production in February and management said it can eventually do ₹800 crore in annual turnover alone. The flagship products from that plant are cooling agents for oral care and confectionery, which Gem is positioning as a tariff-free alternative to Chinese imports. That's the core pitch: a China Plus One play for a specific ingredient niche. The targets are ambitious for a micro-cap that just switched on a new plant. The open question is execution: whether Dahej can ramp fast enough and whether the cooling-agent orders actually land. Management won't guide for the current year, citing geopolitical and raw-material volatility. That's a prudent hedge, but it leaves investors waiting for the first proof points.

Primary source: BSE · NSE

Gem Aromatics files the same Q4 results again. Nothing is new.

Tipsheet Editorial — Thu, 21 May 2026 21:33:48 GMT

The company's press release recaps already-disclosed FY26 numbers with operational commentary. The core financials were public weeks ago.

What’s new

Gem Aromatics issued a press release summarising Q4 FY26 and full-year FY26 results.
The release adds business commentary but no new financial figures.
The core financial data was already disclosed in earlier filings.

Why it matters

This is a confirmatory filing that adds narrative to numbers the market already has. It does not change a financial model. The concall is flagged as important, so the commentary may carry operational context worth checking.

What we’re watching

Any new guidance or margin outlook from the upcoming concall.
Management commentary on specific business drivers mentioned in the release.

The full read

Gem Aromatics published a press release recapping its Q4 and full-year FY26 results. The numbers aren't new. They were disclosed earlier. This filing adds business commentary but no fresh financials. For an investor, this is a summary, not a source. The real detail, if any, will be on the concall. Not yet.

Primary source: BSE · NSE

Gem Aromatics profit falls 97% in FY26; directors waive pay

Tipsheet Editorial — Thu, 21 May 2026 18:38:37 GMT

Consolidated net profit plunged to ₹1.4 crore from ₹53.4 crore as revenue shrank 27%. All three executive directors gave up their salaries.

What’s new

Consolidated net profit collapsed 97% to ₹1.4 crore in FY26 from ₹53.4 crore.
Revenue fell 27% to ₹366.5 crore; standalone profit declined 53% to ₹26.7 crore.
All three executive directors waived their remuneration for the year.

Why it matters

The near-total profit wipeout happened after a capacity expansion, meaning new assets are generating losses instead of returns. Higher raw-material and finance costs swamped a 27% revenue drop. The executive directors waiving their salaries is a rare public concession that the year was a disaster.

What we’re watching

Whether the new capacity can drive volume growth to offset cost pressures in FY27.
If the expanded board changes operational strategy.
The gap between standalone and consolidated results in coming quarters.

The full read

Gem Aromatics' consolidated net profit fell to ₹1.4 crore in FY26 from ₹53.4 crore. That is a 97% collapse. Revenue shrank 27% to ₹366.5 crore from ₹504 crore. Standalone profit declined 53% to ₹26.7 crore. The company blamed higher raw-material costs, increased finance charges, and depreciation linked to a recent capacity expansion. All three executive directors (Vipul Parekh, Kaksha Parekh, and Yash Parekh) waived their remuneration for the year. The board also appointed Dinesh Vasu Thekkepanakkal as whole-time director and Nandan Narula as independent director. For a micro-cap, the profit collapse is severe. The new capacity must drive volumes quickly to reverse this trend. It hasn't yet.

Primary source: BSE · NSE